These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
490 related articles for article (PubMed ID: 33993417)
1. Mucosal and transdermal vaccine delivery strategies against COVID-19. Kumar A; Kumar A Drug Deliv Transl Res; 2022 May; 12(5):968-972. PubMed ID: 33993417 [TBL] [Abstract][Full Text] [Related]
2. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection. van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP Front Immunol; 2021; 12():781280. PubMed ID: 34987509 [TBL] [Abstract][Full Text] [Related]
3. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336 [TBL] [Abstract][Full Text] [Related]
11. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism. Amanpour S Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952 [TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic. Shao Y; Wu Y; Feng Y; Xu W; Xiong F; Zhang X Front Med; 2022 Apr; 16(2):185-195. PubMed ID: 35226300 [TBL] [Abstract][Full Text] [Related]
13. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine. Milane L; Amiji M Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669 [TBL] [Abstract][Full Text] [Related]
14. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions. Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087 [TBL] [Abstract][Full Text] [Related]
15. Intranasal COVID-19 vaccines: From bench to bed. Alu A; Chen L; Lei H; Wei Y; Tian X; Wei X EBioMedicine; 2022 Feb; 76():103841. PubMed ID: 35085851 [TBL] [Abstract][Full Text] [Related]
16. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318 [TBL] [Abstract][Full Text] [Related]
17. The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity. Del Fresno C; García-Arriaza J; Martínez-Cano S; Heras-Murillo I; Jarit-Cabanillas A; Amores-Iniesta J; Brandi P; Dunphy G; Suay-Corredera C; Pricolo MR; Vicente N; López-Perrote A; Cabezudo S; González-Corpas A; Llorca O; Alegre-Cebollada J; Garaigorta U; Gastaminza P; Esteban M; Sancho D Front Immunol; 2021; 12():748103. PubMed ID: 34867974 [TBL] [Abstract][Full Text] [Related]
18. Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges. Abdullahi IN; Emeribe AU; Adekola HA; Abubakar SD; Dangana A; Shuwa HA; Nwoba ST; Mustapha JO; Haruna MT; Olowookere KA; Animasaun OS; Ugwu CE; Onoja SO; Gadama AS; Mohammed M; Daneji IM; Amadu DO; Ghamba PE; Onukegbe NB; Shehu MS; Isomah C; Babayo A; Ahmad AE Hum Vaccin Immunother; 2021 Mar; 17(3):620-637. PubMed ID: 32936732 [TBL] [Abstract][Full Text] [Related]
19. An overview on inactivated and live-attenuated SARS-CoV-2 vaccines. Khoshnood S; Arshadi M; Akrami S; Koupaei M; Ghahramanpour H; Shariati A; Sadeghifard N; Heidary M J Clin Lab Anal; 2022 May; 36(5):e24418. PubMed ID: 35421266 [TBL] [Abstract][Full Text] [Related]
20. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]